Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952508 | 0.93 | PAOX (0.47) | PAOXSIGMAR1ALDH1A1MEN1RAD52 | |
| SCHEMBL986238 | 0.89 | HRH3 (0.46) | PAOXTSHRHIF1A | |
| SCHEMBL984275 | 0.89 | HRH3 (0.46) | PAOXTSHRHIF1A | |
| SCHEMBL2561862 | 0.84 | SIGMAR1 (0.46) | PAOXSIGMAR1ALDH1A1MEN1RAD52 | |
| SCHEMBL678971 | 0.82 | HRH3 (0.56) | SIGMAR1ALDH1A1TSHRHIF1A | |
| SCHEMBL2592744 | 0.81 | TSHR (0.54) | TSHR | |
| SCHEMBL6663287 | 0.81 | PAOX (0.60) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL20234244 | 0.81 | PAOX (0.60) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL7293982 | 0.80 | HRH3 (0.61) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7289625 | 0.80 | TSHR (0.56) | SIGMAR1ALDH1A1TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | SGMS2, PHOSPHO1, SGMS1 | PAOX 2277/4885SIGMAR1 3278/4885ALDH1A1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.